SummaryThe COVID-19 pandemic limits pricing policy options for vaccines. It is therefore necessary to consider what appropriate policy options governments can use to ensure affordable and equitable access to these novel products. Commonly used policies such as fostering competition, generic substitution, and external and internal reference pricing will not work for novel vaccines.

AbstractTo maintain momentum towards improved malaria control and elimination, a vaccine would be a key addition to the intervention toolkit.

In 1997, Milstien, Batson, and Meaney published ‘‘A Systematic Method for Evaluating the Potential Viability of Local Vaccine Producers.” The paper identified characteristics of successful vaccine manufacturers and developed a viability framework to evaluate their performance. This paper revisits the original study after two decades to determine the ability of the framework to predict manufacturer success. Considering the marked changes in the market and technology landscape since 1997, the authors find the viability framework to be predictive and a useful lens through which to evaluate manufacturer success or failure.

Subscribe to RSS - vaccines